Product Main

Quick Details

Purity: 99%
Brand Name: musclesteroids
Grade Standard: Medicine Grade
Type: Pharmaceutical
Place of Origin: China (Mainland)
Other Names: Tacrolimus
CAS No.: 104987-11-3
Origin of place: Made in China
Package: Discreet package
Packing: 10g/50g/100g/1000g
Departure port: HONGKONG/SHENZHEN/SHANGHAI/WUHAN
Destination: Global market

Specifications

Product Name: Tacrolimus CAS: 104987-11-3
Synonyms: (2-propenyl)-, (3s-(3r*(e(1s*, 3s*, 4s*)), 4s*, 5r*, 8s*, 9e, 12r*, 14r*, 15s*, 16r*, 18s*;, 19s*, 26ar*))-; 16-dimethoxy-4,10,12,18-tetramethyl-8-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1;19-epoxy-3h-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h, 23h)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dim; 6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-5; fr900506; prograf; tsukubaenolide
CAS: 104987-11-3
MF: C44H69NO12
MW: 804.02
Product Categories: Active Pharmaceutical Ingredients; Immunosuppressant. ; Intermediates & Fine Chemicals; Pharmaceuticals; API; Chiral Reagents; Fujimycin, Prograf; antibiotic
mp 113-115°C
storage temp. -20°C
solubility DMSO: > 3 mg/mL
form solid
color white
Chemical Properties White Crystalline Solid
Usage An immunosuppressant that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2. Shown to inhibit the activity of FK-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum Ca+2 release.
Usage FK-506 (Tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system
Usage Tacrolimus (fujimycin) was discovered as a potent inhibitor of IL2 production in a targeted search for novel immunosuppressants. Tacrolimus acts by blocking T cell proliferation in vitro by inhibiting the generation of several lymphokines, notably the original target IL-2. Tacrolimus inhibits the activity of FK-506 binding protein, Ca2+-dependent phosphatase and calcineurin, and activates NF-κB through phosphorylation and degradation of IκBα.
Usage treatment of Cushing's syndrome
Usage For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart .